To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Valsartan
Valsartan is an angiotensin II receptor antagonist, acting on the AT1 subtype. In the U.S., valsartan is indicated for treatment of high blood pressure, of congestive heart failure (CHF), and post-myocardial infarction (MI). It is marketed by Novartis under the trade name Diovan®. In 2005, Diovan® was prescribed more than 12 million times in the United States. A study released by the Journal of Clinical Investigation in 2007 found some efficacy in the use of Valsartan in the treatment and prevention of Alzheimer's Disease although such use is considered to be highly experimental.[1] Additional recommended knowledgeAdministrationOral tablets, containing 40 mg (scored), 80 mg, 160 mg or 320 mg of valsartan. Usual dosage ranges from 40–320 mg daily. In some markets available as a Hard Gelatin Capsule, containing 40mg, 80mg, or 160mg of valsartan. Diovan HCT® contains a combination of Valsartan and hydrochlorothiazide but, unlike Diovan®, is only indicated for hypertension, not for CHF or post-MI. Side effectsMost commonly, headache and dizziness. References
Categories: Angiotensin II receptor antagonists | Novartis |
||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Valsartan". A list of authors is available in Wikipedia. |